|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
One of the integrated HBV DNAs was found to lie close to the hst-1, and the hst-1 and the integrated HBV DNA were found to be co-amplified.
|
2856253 |
1988 |
|
Secondary malignant neoplasm of kidney
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although rearrangement of the gene was not detected in any of these samples, amplification of the hst-1 gene was found in 4 samples of tumors, including an invasive bladder cancer, both primary esophageal cancer and its lymph node metastasis, and kidney metastasis of an esophageal cancer.
|
3133332 |
1988 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
(2) The human homolog of int-2, located on chromosome 11q13, is frequently amplified in human primary tumors and is comprised in an amplification unit encompassing the hst gene, which is often coamplified; the amplification at the 11q13 locus in breast carcinomas correlates with a poor outcome of the disease.
|
2677918 |
1989 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although evaluation of the clinical significance of HST amplification and expression must await long-term follow-up of the patients, we suggest that HST gene product could play a role in development and/or progression of human breast cancer.
|
2474139 |
1989 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
Although evaluation of the clinical significance of HST amplification and expression must await long-term follow-up of the patients, we suggest that HST gene product could play a role in development and/or progression of human breast cancer.
|
2474139 |
1989 |
|
Carcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
No coamplification of the hst-1 and int-2 genes was detected in gastric carcinomas and colorectal carcinomas.
|
2529025 |
1989 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
These results suggest that amplification of chromosomal locus of the hst-1 and int-2 genes might participate in carcinogenesis, in progression, and particularly in metastasis of esophageal carcinomas.
|
2529025 |
1989 |
|
Colorectal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
No coamplification of the hst-1 and int-2 genes was detected in gastric carcinomas and colorectal carcinomas.
|
2529025 |
1989 |
|
Bladder Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
None of 37 hematopoietic neoplasms, one out of 13 melanomas (8%), three out of 43 bladder tumors (7%) and 41 out of 238 breast carcinomas (17%) contained amplified FGF-related sequences, namely HST and INT2.
|
2474139 |
1989 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In an attempt to probe the significance of HST and INT-2 gene amplification in human breast carcinomas, we have surveyed the amplification status of five molecular markers located on the long arm of chromosome 11 (BCL-1, HST, INT-2 & SEA on 11q13, and ETS-1 on 11q23) in a population of 297 mammary tumors.
|
2181375 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast to controls, K-fgf-transfected cells secrete significant amounts of biologically active K-fgf protein into the growth media, show up to 50-fold increased colony formation in soft agar, and grow into rapidly progressing, highly vascularized tumors in athymic nude mice.
|
1964794 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Only four proto-oncogenes were found to be amplified in at least one tumor each: HST and INT2 (x3), MYC (x2-3), and FES (x greater than 10).
|
2177639 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The fact that we never observed amplification of HST & INT-2 independently of BCL-1, which in turn can be amplified solely, suggests the presence, between HST/INT-2 and BCL-1, of a genetic element which could be important in the development of a subset of mammary tumors.
|
2181375 |
1990 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas.
|
2098274 |
1990 |
|
Carcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas.
|
2098274 |
1990 |
|
Carcinoma
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Concerning band q13: (i) 50 tumors (approximately 17%) were co-amplified for BCL-1, HST & INT-2; (ii) in 3 cases, amplification extended to the SEA gene; (iii) in 6 carcinomas, BCL-1 was the only amplified marker.
|
2181375 |
1990 |
|
Germ Cell Cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Hst-1/kFGF and bFGF are commonly expressed in five of seven male germ cell cancer lines.
|
2158037 |
1990 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The glutathione S-transferase gene (GST pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer.
|
1826346 |
1991 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BCL1 and two proto-oncogenes, INT2 and HST, were previously found to be coamplified in approximately 1/5 breast carcinomas.
|
2071147 |
1991 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
|
1826346 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Coamplification of GST pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST pi and HSTF1 without amplification of INT2 in another tumor.
|
1826346 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, known genes within the amplified region, such as the FGF-related oncogenes INT-2 and HST-1, are very rarely expressed in these tumors.
|
2011398 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant association between tumor stage and hst-1 expression in the nonseminoma group was found (P = 0.0002, chi 2 test).
|
1706218 |
1991 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that int-2/hst-1 coamplification is a new biological indicator of prognosis and distant organ metastasis in patients with esophageal squamous cell carcinoma.
|
1997190 |
1991 |
|
Carcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
The telomeric one includes the D11S146/BCL1/INT2/HST area and is relevant to DNA amplification in carcinomas and to B-cell translocations.
|
2071147 |
1991 |